Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial

doi:10.4239/wjd.v17.i3.114002

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(42)

(44)

(0)

(10)

(864)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Mar 15, 2026; 17(3): 114002
Published online Mar 15, 2026. doi: 10.4239/wjd.v17.i3.114002

Table 6 Subgroup results of fluorescein angiography scale evaluation, mean ± SD

Fluorescein angiography scale evaluation	Subgroup	n (CDDP/placebo)	CDDP changes from 24 weeks to baseline	Placebo changes from 24 weeks to baseline	Within-group comparison statistic (Wilcoxon rank-sum test)	95%CI	P value
NPDR severity	Mild	127/48	-0.35 ± 1.63	0.00 ± 0.77	2.114	-0.83 to 0.14	0.034
	Moderate	182/56	-0.26 ± 1.98	0.02 ± 1.97	0.753	-0.87 to 0.32	0.451
	Severe	53/17	-0.40 ± 2.78	0.35 ± 1.22	0.779	-2.14 to 0.64	0.431
HbA1c	< 7%	197/64	-0.41 ± 1.97	0.00 ± 1.83	1.109	-0.96 to 0.14	0.267
HbA1c	≥ 7%	163/55	-0.19 ± 2.04	0.09 ± 1.01	1.484	-0.85 to 0.28	0.138
Duration of diabetes	< 5 years	57/23	-0.49 ± 3.08	-0.22 ± 0.52	0.343	-1.57 to 1.02	0.727
Duration of diabetes	≥ 5 years	305/98	-0.28 ± 1.73	0.12 ± 1.63	2.239	-0.79 to -0.01	0.025

NPDR: Non-proliferative diabetic retinopathy; CDDP: Compound danshen dripping pill.

Full Size Table

Citation: An XD, Zhang GL, Zhang YH, Jin D, Ji HY, Wei LJ, He YL, Zheng YL, Li DJ, Wu XW, Li YB, Zhou J, Tan SJ, Zhang MC, Fan K, Lu S, Yu JS, Wang YL, Chen SJ, Liu QH, Jin M, Wu L, Lian FM, Tong XL. Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial. World J Diabetes 2026; 17(3): 114002
URL: https://www.wjgnet.com/1948-9358/full/v17/i3/114002.htm
DOI: https://dx.doi.org/10.4239/wjd.v17.i3.114002

An XD, Zhang GL, Zhang YH, Jin D, Ji HY, Wei LJ, He YL, Zheng YL, Li DJ, Wu XW, Li YB, Zhou J, Tan SJ, Zhang MC, Fan K, Lu S, Yu JS, Wang YL, Chen SJ, Liu QH, Jin M, Wu L, Lian FM, Tong XL. Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial. World J Diabetes 2026; 17(3): 114002 [DOI: 10.4239/wjd.v17.i3.114002]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.